1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Guo Xufeng: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma Tislelizumab - Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy | Phase 2 | Recruiting | Guo Xufeng | 73 | 2023-09-07 | 2023-09-28 |
Esophageal Squamous Cell Carcinoma (1)
Albumin-Bound Paclitaxel (1) · Carboplatin (1) · tislelizumab (1)
China (1)
Changqing Pan (1)